IL7 and pancreatic neoplasm: Another ongoing clinical trial (NCT03932565) evaluates intratumoral injection of Nectin4/FAP-targeted fourth-generation CAR-T cells (expressing IL-7 and CCL19, or IL12) for the treatment of Nectin4-positive advanced malignant solid tumors (NSCLC, breast, ovarian, bladder or pancreatic cancer).